ALKSAlkermes plc.

Nasdaq alkermes.com


$ 26.80 $ 0.46 (1.75 %)    

Friday, 02-Aug-2024 10:21:05 EDT
QQQ $ 445.27 $ -6.57 (-1.46 %)
DIA $ 396.42 $ -2.33 (-0.59 %)
SPY $ 529.77 $ -7.52 (-1.4 %)
TLT $ 97.66 $ 0.03 (0.03 %)
GLD $ 228.35 $ 0.34 (0.15 %)
$ 26.86
$ 26.34
$ 26.75 x 200
$ 26.78 x 102
$ 26.34 - $ 26.97
$ 20.46 - $ 32.88
2,267,964
na
4.59B
$ 0.53
$ 15.70
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-24-2024 06-30-2024 10-Q
2 05-01-2024 03-31-2024 10-Q
3 02-21-2024 12-31-2023 10-K
4 10-25-2023 09-30-2023 10-Q
5 07-26-2023 06-30-2023 10-Q
6 04-26-2023 03-31-2023 10-Q
7 02-16-2023 12-31-2022 10-K
8 11-02-2022 09-30-2022 10-Q
9 07-27-2022 06-30-2022 10-Q
10 04-27-2022 03-31-2022 10-Q
11 02-16-2022 12-31-2021 10-K
12 10-27-2021 09-30-2021 10-Q
13 07-28-2021 06-30-2021 10-Q
14 04-28-2021 03-31-2021 10-Q
15 02-11-2021 12-31-2020 10-K
16 10-29-2020 09-30-2020 10-Q
17 07-29-2020 06-30-2020 10-Q
18 04-29-2020 03-31-2020 10-Q
19 02-13-2020 12-31-2019 10-K
20 10-23-2019 09-30-2019 10-Q
21 07-25-2019 06-30-2019 10-Q
22 04-25-2019 03-31-2019 10-Q
23 02-15-2019 12-31-2018 10-K
24 10-23-2018 09-30-2018 10-Q
25 07-26-2018 06-30-2018 10-Q
26 04-26-2018 03-31-2018 10-Q
27 02-16-2018 12-31-2017 10-K
28 10-26-2017 09-30-2017 10-Q
29 07-27-2017 06-30-2017 10-Q
30 04-27-2017 03-31-2017 10-Q
31 02-17-2017 12-31-2016 10-K
32 11-02-2016 09-30-2016 10-Q
33 07-28-2016 06-30-2016 10-Q
34 04-28-2016 03-31-2016 10-Q
35 02-25-2016 12-31-2015 10-K
36 10-29-2015 09-30-2015 10-Q
37 07-30-2015 06-30-2015 10-Q
38 04-30-2015 03-31-2015 10-Q
39 02-24-2015 12-31-2014 10-K
40 10-29-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-reiterates-overweight-on-alkermes-maintains-48-price-target

Cantor Fitzgerald analyst Charles Duncan reiterates Alkermes (NASDAQ:ALKS) with a Overweight and maintains $48 price target.

 jp-morgan-maintains-neutral-on-alkermes-raises-price-target-to-32

JP Morgan analyst Jessica Fye maintains Alkermes (NASDAQ:ALKS) with a Neutral and raises the price target from $31 to $32.

 baird-maintains-outperform-on-alkermes-raises-price-target-to-38

Baird analyst Joel Beatty maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price target from $37 to $38.

 hc-wainwright--co-maintains-neutral-on-alkermes-raises-price-target-to-37

HC Wainwright & Co. analyst Douglas Tsao maintains Alkermes (NASDAQ:ALKS) with a Neutral and raises the price target fro...

 jp-morgan-maintains-neutral-on-alkermes-lowers-price-target-to-31

JP Morgan analyst Jessica Fye maintains Alkermes (NASDAQ:ALKS) with a Neutral and lowers the price target from $32 to $31.

 td-cowen-initiates-coverage-on-alkermes-with-buy-rating-announces-price-target-of-34

TD Cowen analyst Joseph Thome initiates coverage on Alkermes (NASDAQ:ALKS) with a Buy rating and announces Price Target of $34.

 hc-wainwright--co-reiterates-neutral-on-alkermes-maintains-35-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:ALKS) with a Neutral and maintains $35 price target.

 alkermes-unveils-phase-1b-data-for-narcolepsy-treatment-at-sleep-2024

 Alkermes plc (NASDAQ:ALKS) today announced new data from the full narcolepsy type 1 (NT1) cohort of a phase 1b, proof-of-conce...

 alkermes-to-present-promising-narcolepsy-treatment-data-at-annual-sleep-conference

Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024 PRNewswire – Late-Breaking Abstracts Containing Data From t...

 cantor-fitzgerald-maintains-overweight-on-alkermes-raises-price-target-to-48

Cantor Fitzgerald analyst Charles Duncan maintains Alkermes (NASDAQ:ALKS) with a Overweight and raises the price target from...

 hc-wainwright--co-reiterates-neutral-on-alkermes-maintains-35-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:ALKS) with a Neutral and maintains $35 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION